Liver transplantation for hepatocellular carcinoma: Role of inflammatory and immunological state on recurrence and prognosis

World Journal of Gastroenterology

Volumn 19, Issue 48, 2013, Pages 9174-9182

  Cescon, Matteo ^a   Bertuzzo, Valentina Rosa ^a   Ercolani, Giorgio ^a   Ravaioli, Matteo ^a   Odaldi, Federica ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hepatocellular carcinoma; Immunosuppression; Inflammation; Liver transplantation; Recurrence

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTITHYMOCITE GLOBULIN; BASILIXIMAB; BILIRUBIN; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CD163 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; EVEROLIMUS; GRANZYME A; GRANZYME B; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PERFORIN; RAPAMYCIN; STEROID; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE ASSOCIATION; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; HODGKIN DISEASE; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE COUNT; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SCORING SYSTEM; SURVIVAL RATE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

HEPATOCELLULAR CARCINOMA; IMMUNOSUPPRESSION; INFLAMMATION; LIVER TRANSPLANTATION; RECURRENCE;

CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INFLAMMATION MEDIATORS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84891391095     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i48.9174     Document Type: Article

References (69)

1. International Agency for Research on Cancer, 2011. Available from: URL: http //www.iarc.fr/. Accessed July 20, 2013
2. Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation-an emerging clinical challenge. Transpl Int 2013; 26: 109-118 [PMID: 22994652 DOI: 10.1111/j.1432-2277.2012.01562]
3. Sotiropoulos GC, Molmenti EP, Lösch C, Beckebaum S, Broelsch CE, Lang H. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res 2007; 12: 527-534 [PMID: 18024261]
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428]
5. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 [PMID: 19058754 DOI: 10.1016/ S1470-2045(08)70284-5]
6. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253: 166-172 [PMID: 21294289 DOI: 10.1097/SLA.0b013e31820508f1]
7. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862 [PMID: 18948815 DOI: 10.1097/ SLA.0b013e3181896278]
8. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, Onaca N, Goldstein R, Levy M, Klintmalm GB. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834-1842 [PMID: 19938137 DOI: 10.1002/lt.21953]
9. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-1596 [PMID: 18669577 DOI:10.1136/gut.2008.149062]
10. van der Poorten D, Kwok A, Lam T, Ridley L, Jones DB, Ngu MC, Lee AU. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J 2006; 36: 692-699 [PMID: 17040353 DOI: 10.1111/j.1445-5994.2006.01216.x]
11. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, Morris LS, Coleman N, Alexander GJ. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45: 246-253 [PMID: 16580084 DOI: 10.1016/j.jhep.2005.12.027]
12. Mathai AM, Kapadia MJ, Alexander J, Kernochan LE, Swanson PE, Yeh MM. Role of Foxp3-positive tumorinfiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma. Am J Surg Pathol 2012; 36: 980-986 [PMID: 22446942 DOI: 10.1097/ PAS.0b013e31824e9b7c]
13. Cheng JW, Shi YH, Fan J, Huang XW, Qiu SJ, Xiao YS, Wang Z, Dai Z, Tang ZY, Zhou J. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137: 1445-1453 [PMID: 21809031 DOI: 10.1007/s00432-011-1014-0]
14. An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, Lee MA, You YK, Kim DG, Jung ES. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2012; 18: 1406-1414 [PMID: 22821639]
15. Halazun KJ, Hardy MA, Rana AA, Woodland DC, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown RS, Emond JC. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141-151 [PMID: 19561458 DOI:10.1097/SLA.0b013e3181a77e59]
16. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'Errico-Grigioni A, Golfieri R, Pinna AD. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011; 91: 1279-1285 [PMID: 21617590 DOI: 10.1097/ TP.0b013e3182187cf0]
17. Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q, Chen GH. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One 2011; 6: e25295 [PMID: 21966488 DOI: 10.1371/journal. pone.0025295]
18. Limaye AR, Clark V, Soldevila-Pico C, Morelli G, Suman A, Firpi R, Nelson DR, Cabrera R. Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res 2013; 43: 757-764 [PMID: 23193965 DOI: 10.1111/hepr.12019]
19. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013; 58: 58-64 [PMID: 22925812 DOI: 10.1016/ j.jhep.2012.08.017]
20. Yoshizumi T, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, Ikeda T, Soejima Y, Shirabe K, Maehara Y. Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res 2013; 43: 709-716 [PMID: 23190306 DOI:10.1111/hepr.12016]
21. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004 [PMID: 18923165 DOI: 10.1056/NEJMoa0804525]
22. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM. MicroRNAbased classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011; 140: 1618-1628. e16 [PMID: 21324318 DOI: 10.1053/j.gastro.2011.02.009]
23. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140: 1501-12. e2 [PMID: 21320499 DOI: 10.1053/j.gastro.2011.02.006]
24. Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, La Barba G, Brillanti S, Cavallari A. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002; 74: 1746-1751 [PMID: 12499891]
25. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-1311 [PMID: 15376305 DOI: 10.1002/ lt.20237]
26. Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, Pinna AD. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497-503 [PMID: 15838913 DOI: 10.1002/lt.20391]
27. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Compagnon P, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouillères O, Cherqui D, Duvoux C. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319-7325 [PMID: 17143948]
28. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40: 3548-3553 [PMID: 19100435 DOI: 10.1016/j.transproceed.2008.03.165]
29. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633-638 [PMID: 18324656 DOI:10.1002/lt.21420]
30. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89: 227-231 [PMID: 20098287 DOI: 10.1097/TP.0b013e3181c3c540]
31. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243 [PMID: 20187107 DOI: 10.1002/hep.23437]
32. Xing T, Huang L, Yu Z, Zhong L, Wang S, Peng Z. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma. PLoS One 2013; 8: e71251 [PMID: 23940730 DOI: 10.1371/journal.pone.0071251]
33. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199 [PMID: 23867318 DOI: 10.1016/j.jhep.2013.07.012]
34. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684]
35. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867 [PMID: 12490959]
36. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]
37. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003; 90: 215-219 [PMID: 12555298 DOI: 10.1002/bjs.4038]
38. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413-2418 [PMID: 16214925 DOI: 10.1158/1055-9965. EPI-05-0316]
39. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585-590 [PMID: 14762037 DOI: 10.1001/jama.291.5.585]
40. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103: 1856-1864 [PMID: 15779015 DOI: 10.1002/ cncr.20976]
41. Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-1186 [PMID: 1699862]
42. Kawai Y, Matsuyama H, Korenaga Y, Misumi T, Eguchi S, Hara T, Nagao K, Ohmi C, Sakano S, Naito K. Preoperative erythrocyte sedimentation rate is an independent prognostic factor in Japanese patients with localized clear cell renal cell carcinoma. Urol Int 2009; 83: 306-310 [PMID: 19829031 DOI:10.1159/000241673]
43. Lehmann J, Retz M, Nürnberg N, Schnöckel U, Raffenberg U, Krams M, Kellner U, Siemer S, Weichert-Jacobsen K, Stöckle M. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 2004; 101: 1552-1562 [PMID: 15378494 DOI:10.1002/cncr.20549]
44. Forslund A, Engarås B, Lönnroth C, Lundholm K. Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA 50, CA 242 and conventional blood tests in patients with colorectal carcinoma. Int J Oncol 2002; 20: 1013-1018 [PMID: 11956598]
45. Bien E, Balcerska A. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma. Scand J Immunol 2009; 70: 490-500 [PMID: 19874554 DOI:10.1111/j.13653083.2009.02313.x]
46. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105 [PMID: 14964307 DOI: 10.1038/nrc1275]
47. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, Altorki NK, Abrams JA. Elevated preoperative neutrophil: lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 2011; 18: 3362-3369 [PMID: 21547702 DOI: 10.1245/s10434-011-1754-8]
48. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184 [PMID: 16118772 DOI:10.1002/jso.20329]
49. Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, Lodge JP, Toogood GJ. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 2007; 246: 806-814 [PMID: 17968173 DOI: 10.1097/SLA.0b013e318142d964]
50. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JP. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34: 55-60 [PMID: 17448623 DOI: 10.1016/j.ejso.2007.02.014]
51. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32: 1757-1762 [PMID: 18340479 DOI: 10.1007/s00268-008-9552-6]
52. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2008; 97: 513-518 [PMID: 18335453 DOI: 10.1002/jso.21001]
53. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200: 197-203 [PMID: 20122680 DOI: 10.1016/ j.amjsurg.2009.08.041]
54. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 2457-2464 [PMID: 15781662 DOI: 10.1158/0008-5472.CAN-04-3232]
55. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339 [PMID: 17570208 DOI: 10.1053/j.gastro.2007.03.102]
56. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, Lobashevsky A, Redfield R, Schweitzer E, Heredia A, Reardon E, Davis C, Bentlejewski C, Fung J, Shapiro R, Zeevi A. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77-88 [PMID: 12709071 DOI: 10.1034/ j.1399-0012.2003.00013.x]
57. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007; 8: 639-646 [PMID: 17486092 DOI: 10.1038/ni1467]
58. Kuang DM, Peng C, Zhao Q, Wu Y, Zhu LY, Wang J, Yin XY, Li L, Zheng L. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol 2010; 185: 1544-1549 [PMID: 20581151 DOI: 10.4049/jimmunol.0904094]
59. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54: 948-955 [PMID: 21145847 DOI: 10.1016/j.jhep.2010.08.041]
60. Kono H, Fujii H, Ogiku M, Hosomura N, Amemiya H, Tsuchiya M, Hara M. Role of IL-17A in neutrophil recruitment and hepatic injury after warm ischemia-reperfusion mice. J Immunol 2011; 187: 4818-4825 [PMID: 21949019 DOI:10.4049/jimmunol.1100490]
61. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78 [PMID: 14708027 DOI: 10.1038/nrc1256]
62. Mano Y, Shirabe K, Yamashita Y, Harimoto N, Tsujita E, Takeishi K, Aishima S, Ikegami T, Yoshizumi T, Yamanaka T, Maehara Y. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg 2013; 258: 301-305 [PMID: 23774313 DOI: 10.1097/SLA.0b013e318297ad6b]
63. Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int 2013 Sep 6; Epub ahead of print [PMID: 24118272 DOI: 10.1111/tri.12191]
64. Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol 2012; 27: 553-561 [PMID: 21913982 DOI:10.1111/j.1440-1746.2011.06910.x]
65. Dan J, Zhang Y, Peng Z, Huang J, Gao H, Xu L, Chen M. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One 2013; 8: e58184 [PMID: 23516447 DOI: 10.1371/journal.pone.0058184]
66. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-8425 [PMID: 15623621 DOI: 10.1158/1078-0432.CCR-04-0941]
67. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42-52 [PMID: 17187432 DOI: 10.1002/hep.21467]
68. Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK. A prospective randomised, openlabeled, trial comparing sirolimus-containing versus mTORinhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190 [PMID: 20459775 DOI: 10.1186/1471-240 7-10-190]
69. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 411-419 [PMID: 23278125 DOI: 10.1111/ apt.12185]